{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:49:25Z","timestamp":1760147365877,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (FCT)","award":["UID\/QUI\/00313\/2020","SFRH\/BD\/133996\/2017","COVID\/BD\/152172\/2021"],"award-info":[{"award-number":["UID\/QUI\/00313\/2020","SFRH\/BD\/133996\/2017","COVID\/BD\/152172\/2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Processes"],"abstract":"<jats:p>Celecoxib, a cyclooxygenase-2 inhibitor (COX-2), is attracting considerable interest owing to its potential anticancer activity. The repurposing strategy of this drug, however, requires preclinical assessment involving the use of increasingly improved analytical methods. In this work, a rapid, accurate, precise, and sensitive reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed for the quantification of celecoxib in five mouse matrices (plasma, brain, spleen, liver, and kidney). Chromatographic separation was achieved within 8 min on a reversed-phase C18 column at 35 \u00b0C using a mixture of acetonitrile and 2% (v\/v) acetic acid (50:50) as mobile phase, at a flow rate of 0.6 mL\/min. Celecoxib and curcumin, as the internal standard, were analyzed at 425 nm and 250 nm, respectively. Linearity was observed (r2 \u2265 0.996) in the concentration ranges selected for celecoxib. Overall precision was below 14.9%, and accuracy was between \u221214.9% and 13.2%. The acceptance criteria specified in FDA and EMA guidelines were met. Celecoxib was reproducibly recovered (\u226584%) and showed stability in all biological matrices at room temperature for 24 h. The method was then effectively applied for the quantification of celecoxib to understand in vivo biodistribution following its intraperitoneal administration in mice.<\/jats:p>","DOI":"10.3390\/pr11020431","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T03:22:47Z","timestamp":1675221767000},"page":"431","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can Celecoxib Assay in Preclinical Studies Be Improved?"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-4517","authenticated-orcid":false,"given":"Maria","family":"Mendes","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Coimbra Chemistry Centre, Institute of Molecular Sciences\u2014IMS, Faculty of Sciences and Technology, University of Coimbra, 3004-535 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9718-8035","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Sousa","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Coimbra Chemistry Centre, Institute of Molecular Sciences\u2014IMS, Faculty of Sciences and Technology, University of Coimbra, 3004-535 Coimbra, Portugal"}]},{"given":"Alberto","family":"Pais","sequence":"additional","affiliation":[{"name":"Coimbra Chemistry Centre, Institute of Molecular Sciences\u2014IMS, Faculty of Sciences and Technology, University of Coimbra, 3004-535 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-548X","authenticated-orcid":false,"given":"Carla","family":"Vitorino","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Coimbra Chemistry Centre, Institute of Molecular Sciences\u2014IMS, Faculty of Sciences and Technology, University of Coimbra, 3004-535 Coimbra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","article-title":"Celecoxib pathways: Pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet. Genom."},{"key":"ref_2","unstructured":"Basso, J., Mendes, M., Fortuna, A., Vitorino, R., Sousa, J., Pais, A., and Vitorino, C. (2020). Drug Repurposing in Cancer Therapy, Elsevier."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2018.04.039","article-title":"Repurposing drugs for glioblastoma: From bench to bedside","volume":"428","author":"Basso","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_4","unstructured":"PubChem (2018, April 03). Celecoxib, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/2662."},{"key":"ref_5","unstructured":"PharmgKB (2021, November 11). Celecoxib. Available online: https:\/\/www.pharmgkb.org\/pathway\/PA152241951."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Alajami, H.N., Fouad, E.A., Ashour, A.E., Kumar, A., and Yassin, A.E.B. (2022). Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010131"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/acsnano.5b04137","article-title":"Celecoxib Nanoparticles for Therapeutic Angiogenesis","volume":"9","author":"Margulis","year":"2015","journal-title":"ACS Nano"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"121278","DOI":"10.1016\/j.ijpharm.2021.121278","article-title":"Transformation of nanoparticles into compacts: A study on PLGA and celecoxib nanoparticles","volume":"611","author":"Li","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.18433\/jpps30912","article-title":"Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: In vitro and in vivo Validation and Application","volume":"23","author":"Ziaei","year":"2020","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jchromb.2012.05.013","article-title":"Determination of celecoxib in human plasma by liquid chromatography\u2013tandem mass spectrometry","volume":"899","author":"Macek","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0378-4347(99)00552-6","article-title":"Determination of celecoxib in human plasma by normal-phase high-performance liquid chromatography with column switching and ultraviolet absorbance detection","volume":"738","author":"Rose","year":"2000","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/chromsci\/43.7.351","article-title":"Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography","volume":"43","author":"Hamama","year":"2005","journal-title":"J. Chromatogr. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e4621","DOI":"10.1002\/bmc.4621","article-title":"Development and full validation of an HPLC methodology to quantify atorvastatin and curcumin after their intranasal co-delivery to mice","volume":"33","author":"Silva","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0731-7085(01)00678-1","article-title":"Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography","volume":"28","author":"Saha","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jchromb.2015.07.026","article-title":"Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS\/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles","volume":"1001","author":"Ma","year":"2015","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_16","unstructured":"EMA\u2014European Medicines Agency (2023, January 30). Guideline on Bioanalytical Method Validation, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.17145\/jab.18.010","article-title":"Bioanalytical Method Development and Validation: From the US FDA 2001 to the US FDA 2018 Guidance for Industry","volume":"4","author":"Meesters","year":"2018","journal-title":"J. Appl. Bioanal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1039\/C8AY01695J","article-title":"Analytical Quality by Design (AQbD) as a multiaddressable platform for co-encapsulating drug assays","volume":"10","author":"Basso","year":"2018","journal-title":"Anal. Methods"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."}],"container-title":["Processes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9717\/11\/2\/431\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:20:27Z","timestamp":1760120427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9717\/11\/2\/431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["pr11020431"],"URL":"https:\/\/doi.org\/10.3390\/pr11020431","relation":{},"ISSN":["2227-9717"],"issn-type":[{"type":"electronic","value":"2227-9717"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}